Deutsche Bank AG Analysts Give Pfizer, Inc. (PFE) a $38.00 Price Target
Pfizer, Inc. (NYSE:PFE) has been assigned a $38.00 target price by analysts at Deutsche Bank AG in a research note issued to investors on Wednesday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Deutsche Bank AG’s target price suggests a potential upside of 4.54% from the stock’s current price.
A number of other analysts also recently issued reports on PFE. Jefferies Group LLC reissued a “neutral” rating and set a $34.00 price target on shares of Pfizer in a report on Friday, June 16th. BidaskClub raised shares of Pfizer from a “strong sell” rating to a “sell” rating in a report on Friday, June 23rd. Cowen and Company set a $43.00 price target on shares of Pfizer and gave the stock a “buy” rating in a report on Monday, July 10th. Zacks Investment Research raised shares of Pfizer from a “sell” rating to a “hold” rating in a report on Friday, July 14th. Finally, Sanford C. Bernstein set a $39.00 price target on shares of Pfizer and gave the stock a “buy” rating in a report on Monday, July 17th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $38.10.
Shares of Pfizer (PFE) traded down 0.27% during mid-day trading on Wednesday, hitting $36.35. 13,994,415 shares of the stock traded hands. Pfizer has a 12 month low of $29.83 and a 12 month high of $36.60. The firm has a 50 day moving average of $35.11 and a 200 day moving average of $33.75. The stock has a market cap of $216.19 billion, a price-to-earnings ratio of 26.59 and a beta of 1.00.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The firm had revenue of $12.90 billion for the quarter, compared to the consensus estimate of $13.08 billion. During the same period in the prior year, the firm posted $0.64 earnings per share. The firm’s quarterly revenue was down 1.9% compared to the same quarter last year. On average, equities analysts expect that Pfizer will post $2.56 EPS for the current fiscal year.
In related news, insider Sally Susman sold 38,230 shares of the firm’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the completion of the sale, the insider now directly owns 145,649 shares in the company, valued at $5,097,715. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Ian C. Read sold 96,950 shares of the firm’s stock in a transaction dated Friday, August 4th. The stock was sold at an average price of $34.00, for a total transaction of $3,296,300.00. The disclosure for this sale can be found here. Insiders sold 464,521 shares of company stock valued at $15,813,961 over the last quarter. Company insiders own 0.06% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in PFE. Asset Planning Services Ltd. increased its position in Pfizer by 4.9% during the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 137 shares during the last quarter. Shine Investment Advisory Services Inc. acquired a new stake in Pfizer during the second quarter worth about $102,000. Mckinley Capital Management LLC Delaware acquired a new stake in Pfizer during the second quarter worth about $103,000. D. Scott Neal Inc. increased its position in Pfizer by 19.3% during the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 504 shares during the last quarter. Finally, Herndon Capital Management LLC acquired a new stake in Pfizer during the second quarter worth about $120,000. Hedge funds and other institutional investors own 68.99% of the company’s stock.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.